Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Irtemazole (R 60844) is a novel uricosuric substance that is valuable in the treatment of hyperuricemia and gout.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 112.00 | |
5 mg | In stock | $ 260.00 | |
10 mg | In stock | $ 390.00 | |
25 mg | In stock | $ 653.00 | |
50 mg | In stock | $ 928.00 | |
100 mg | In stock | $ 1,260.00 | |
500 mg | In stock | $ 2,530.00 |
Description | Irtemazole (R 60844) is a novel uricosuric substance that is valuable in the treatment of hyperuricemia and gout. |
In vivo | Irtemazole (12.5 to 50 mg; oral; 6 patients) caused a maximal decrease in plasma uric acid (after 8 to 12 h) of 46.5%. The uricosuric effect began during the first 60 min after drug administration and it lasted for 7 to 24 h. Renal uric acid excretion returned to its base line value after 8 to 16 h and uric acid clearance after 10.0 to 12.0 h. Doses of irtemazole between 12.5 and 37.5 mg produced a dose-related rise in the uricosuric effect. There was no essential difference between the uricosuric effect of 37.5 mg and 50 mg irtemazole. The D50 dose (that producing a half-maximal effect) was between 16.3 mg and 34.2 mg, (average 24.7 mg). The value of irtemazole in the management of hyperuricaemia and gout remains to be determined.[2] |
Synonyms | R60844, R-60844, R 60844 |
Molecular Weight | 288.35 |
Formula | C18H16N4 |
CAS No. | 129369-64-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (190.74 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Irtemazole 129369-64-8 Others R60844 R-60844 R 60844 inhibitor inhibit